NEXGEL, Inc. (NXGL) Discusses Strategic Platform Reorganization and Refocus on Medical Device and Biomedical Innovation September 24, 2026 4:15 PM EDT
Company Participants
Steven Glassman
Brian Kieser – Interim CEO & Director
Kevin Harris
Conference Call Participants
Nazibur Rahman – Maxim Group LLC, Research Division
Andrew S.M. Dean
Presentation
Operator
Hello, and welcome, everyone, joining today’s NEXGEL Investor Update Conference Call. [Operator Instructions] Please note, this call is being recorded. [Operator Instructions] It is now my pleasure to turn the meeting over to Steven Glassman, Chairman of the Board of Directors.
Steven Glassman
Thank you. Good afternoon, everyone. Welcome to the update call. I just wanted to reiterate, we appreciate everyone’s interest as well as their patience over the past 6 weeks as noted in the press release from the middle of August, just taking a step back and looking at the entire company and the different lines of businesses holistically and determining what is the best way to move forward with shareholder value. So with that said, I’m going to go ahead and turn the call over to Brian Kieser, the Interim Chief Executive Officer, and have Brian start out walking you through the update.
Brian Kieser
Interim CEO & Director
Thank you, Steve. Good afternoon, everyone. My name is Brian Kieser. I have the pleasure of holding the title of Interim Chief Executive Officer of NEXGEL, Inc. I appreciate everybody’s patience again to reiterate what Steve said over the last 6 weeks as we’ve done a strategic review of all of the business and our goal to determine the best path forward for NEXGEL and its shareholders.
What we will discuss today will be really a proposed platform reorganization that our strategic review committee, along with our employees, have worked very, very hard on over the last 6 weeks. And before I